Ledger.Open graph →
SEC Form D · filed July 27, 2018

Nabriva Therapeutics plc

Offering
$26.9M
Sold
$21.3M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
DUBLIN 1, Ireland
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (15)

Gary A. Sender · King of Prussia, PAExecJennifer M. Schranz · King of Prussia, PAExecAxel Bolte · New York, NYDirectorGary A. Sender · San Diego, CAExecTheodore Schroeder · King of Prussia, PAExec · DirectorRobert A. Crotty · King of Prussia, PAExecColin A. Broom · King of Prussia, PADirectorFrancesco M. Lavino · King of Prussia, PAExecSteven A. Gelone · King of Prussia, PAExecStephen H. Webster · King of Prussia, PADirectorDaniel Burgess · Waltham, MADirectorCarrie A. Bourdow · King of Prussia, PADirectorMark H. Corrigan · King of Prussia, PADirectorGeorge H. Talbot · King of Prussia, PADirectorCharles A. Rowland · King of Prussia, PADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗